Small-scale bioreactor supports high density HEK293 cell perfusion culture for the production of recombinant Erythropoietin.


Journal

Journal of biotechnology
ISSN: 1873-4863
Titre abrégé: J Biotechnol
Pays: Netherlands
ID NLM: 8411927

Informations de publication

Date de publication:
10 Feb 2020
Historique:
received: 15 01 2019
revised: 11 12 2019
accepted: 26 12 2019
pubmed: 1 1 2020
medline: 15 9 2020
entrez: 1 1 2020
Statut: ppublish

Résumé

Process intensification in mammalian cell culture-based recombinant protein production has been achieved by high cell density perfusion exceeding 10

Identifiants

pubmed: 31891733
pii: S0168-1656(19)30953-8
doi: 10.1016/j.jbiotec.2019.12.017
pii:
doi:

Substances chimiques

Recombinant Proteins 0
Erythropoietin 11096-26-7
Oxygen S88TT14065

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-52

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hubert Schwarz (H)

School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Dept. of Industrial Biotechnology, Cell Technology Group (CETEG), Royal Institute of Technology (KTH), Stockholm, Sweden; Wallenberg Centre for Protein Research (WCPR), Stockholm, Sweden; Centre for Advanced Bioproduction by Continuous Processing (AdBIOPRO), Stockholm, Sweden.

Ye Zhang (Y)

School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Dept. of Industrial Biotechnology, Cell Technology Group (CETEG), Royal Institute of Technology (KTH), Stockholm, Sweden; Wallenberg Centre for Protein Research (WCPR), Stockholm, Sweden; Centre for Advanced Bioproduction by Continuous Processing (AdBIOPRO), Stockholm, Sweden.

Caijuan Zhan (C)

School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Dept. of Industrial Biotechnology, Cell Technology Group (CETEG), Royal Institute of Technology (KTH), Stockholm, Sweden; Wallenberg Centre for Protein Research (WCPR), Stockholm, Sweden.

Magdalena Malm (M)

Wallenberg Centre for Protein Research (WCPR), Stockholm, Sweden; School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Dept. of Protein Science, Royal Institute of Technology (KTH), Stockholm, Sweden.

Raymond Field (R)

BioPharmaceutical Development, AstraZeneca, Cambridge, UK.

Richard Turner (R)

BioPharmaceutical Development, AstraZeneca, Cambridge, UK.

Christopher Sellick (C)

BioPharmaceutical Development, AstraZeneca, Cambridge, UK; Kymab, Cambridge, UK.

Paul Varley (P)

BioPharmaceutical Development, AstraZeneca, Cambridge, UK.

Johan Rockberg (J)

Wallenberg Centre for Protein Research (WCPR), Stockholm, Sweden; School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Dept. of Protein Science, Royal Institute of Technology (KTH), Stockholm, Sweden.

Véronique Chotteau (V)

School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Dept. of Industrial Biotechnology, Cell Technology Group (CETEG), Royal Institute of Technology (KTH), Stockholm, Sweden; Wallenberg Centre for Protein Research (WCPR), Stockholm, Sweden; Centre for Advanced Bioproduction by Continuous Processing (AdBIOPRO), Stockholm, Sweden. Electronic address: veronique.chotteau@biotech.kth.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH